Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Anti-inflammatory drugs industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug class trends
2.1.4 Treatment trends
2.1.5 Route of administration trends
2.1.6 Sales channel trends
Chapter 3 Anti-inflammatory Drugs Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of inflammatory diseases
3.2.1.2 Increasing advancements in anti-inflammatory drugs development
3.2.1.3 Rising incidences of autoimmune disease and respiratory conditions
3.2.1.4 Growing geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory approval
3.2.2.2 Side effects associated with anti-inflammatory drugs
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By treatment
3.3.3 By route of administration
3.3.4 By sales channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6 Application potential
3.7 Technology landscape
3.8 Pipeline analysis
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategy outlook matrix
Chapter 5 Anti-inflammatory Drugs Market Size and Forecast, By Drug Class (USD Million)
5.1 Key trends, by drug class
5.2 Anti-inflammatory biologics
5.3 Nonsteroidal anti-inflammatory drugs (NSAIDS)
5.4 Corticosteroids
5.5 Other drug class
Chapter 6 Anti-inflammatory Drugs Market Size and Forecast, By Treatment (USD Million)
6.1 Key trends, by treatment
6.2 Arthritis
6.3 Inflammatory bowel disease (IBD)
6.4 Chronic obstructive pulmonary disease (COPD)
6.5 Multiple sclerosis
6.6 Other treatments
Chapter 7 Anti-inflammatory Drugs Market Size and Forecast, By Route of Administration (USD Million)
7.1 Key trends, by route of administration
7.2 Oral
7.3 Topical
7.4 Injection
7.5 Intranasal
Chapter 8 Anti-inflammatory Drugs Market Size and Forecast, By Sales Channel (USD Million)
8.1 Key trends, by sales channel
8.2 Prescription
8.3 Over the Counter (OTC)
Chapter 9 Anti-inflammatory Drugs Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of MEA
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Bristol-Myers Squibb Company
10.3 Merck & Co., Inc.
10.4 Pfizer Inc.
10.5 Novartis AG
10.6 Johnson & Johnson
10.7 Amgen Inc
10.8 Eli Lilly and Company
10.9 Sun Pharmaceutical Industries Ltd
10.10 GlaxoSmithKline plc
10.11 Hoffmann-La Roche AG
10.12 AstraZeneca plc
10.13 Abbott Laboratories
